Exploring the link between immunoglobulin deficiency and fatigue in multiple sclerosis patients
Official title: Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)? - A Prospective Observational Fatigue Trial
Run by Insel Gruppe AG, University Hospital Bern · NCT05357781 · Data updated 2026-11-12
This study is trying to see if low levels of a certain antibody in people with multiple sclerosis can be a cause of their fatigue and if treating it could help them feel better.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 106 (estimated) |
| Sponsor | Insel Gruppe AG, University Hospital Bern Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Bern, Canton of Bern) |
| Status | Recruiting |
| Started | July 1, 2022 |
| Main results expected | December 30, 2026 |
| Study ends | December 30, 2026 |
| Registry record updated | May 1, 2026 |
| Trial ID | NCT05357781 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18-65 with a stable diagnosis of multiple sclerosis and no significant psychiatric or immunodeficiency issues.
✕Probably not a fit
Patients with severe depression, other forms of immunodeficiency, or those already receiving immunoglobulin replacement therapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate whether hypogammaglobulinemia, characterized by low IgG serum levels, is a treatable cause of fatigue in patients with multiple sclerosis (MS). The primary objective is to establish a connection between hypogammaglobulinemia and fatigue, while the secondary objective focuses on understanding if fatigue is exacerbated by frequent infections in these patients. The study will involve laboratory tests to assess immunoglobulin levels in individuals diagnosed with MS who meet specific inclusion criteria. By identifying potential treatable factors contributing to fatigue, the study seeks to improve the quality of life for MS patients.
Why it matters
Potential benefit: If successful, this study could lead to new treatment options for fatigue in multiple sclerosis patients by addressing underlying immunoglobulin deficiencies.
How similar studies have gone: While studies have shown correlations between immunoglobulin therapy and fatigue in other conditions, this specific approach in multiple sclerosis is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of Multiple Sclerosis following McDonald 2017-Criteria * Age 18-65 years * Stable MS disease at inclusion (definition: no clinical relapse, no MRI activity, stable disability within the last 12 months) * Unchanged immunotherapy within the last 12 months * Expanded Disability Status Scale (EDSS) level \<4 points indicating fully ambulatory patients. * Capability of written informed consent Exclusion Criteria: * Severe depression (definition: Beck Depression Index-II (BDI-II) ≥29 points) or other established psychiatric diagnosis * Immunodeficiency other than hypogammaglobulinemia * Immunglobulin replacement therapy or indication for immunoglobulin replacement therapy * Severe Sleepiness (definition: Epworth-Sleepiness-Scale (ESS) \>16 points) * Fatigue aggravating factors such: liver/renal/thyroid dysfunction, substance abuse, medication (tranquilizers /antiepileptics/psychopharmaceuticals), chronic infectious disease (like hepatitis/HIV). * Other neurodegenerative/autoimmune disease. * Patients not able to give written consent * Vulnerable patients such as children, pregnant women and prisoners
Where it's running
-
University Hospital of Bern Inselspital
Bern, Canton of Bern, Switzerland Recruiting
Study contacts
- Principal investigator: Lara Diem, MD — Inselspital University Hospital of Bern
- Study coordinator: Lara Diem, MD
- Email: larafrancesca.diem@insel.ch
- Phone: 0041316327000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Balance and gait in multiple sclerosis: linking motion data to function
Researchers will see if precise motion measurements of balance and walking relate to everyday functional tests in adults with MS.
-
Remotely Delivered Pilates for MS: Walking, Balance, Fatigue, Mood and Quality of Life
A 16-week remote Pilates program will be tested to see if it helps walking, balance, fatigue, pain, mood, thinking, and quality of life for people with multiple sclerosis who can participate from home.
-
Sexual problems in women with relapsing-remitting multiple sclerosis
See if sexual dysfunction is common in women aged 25-50 with relapsing-remitting MS and whether it's linked to fatigue, mood, bladder symptoms, and cognitive problems.
-
Comparing eccentric and traditional exercise on fatigue in multiple sclerosis
This study is testing whether eccentric exercise is better than traditional exercise for reducing fatigue in people with multiple sclerosis.
-
Treadmill-based virtual reality walking training for MS patients
This study tests whether a treadmill with virtual reality and smart socks can help people with multiple sclerosis walk better and feel safer in daily life.
-
Virtual Reality and Mental Practice to Improve Balance and Walking in Relapsing MS
This study tests whether virtual reality training or mental practice can improve balance and walking in people with relapsing–remitting multiple sclerosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.